Risk factors for treatment failure with antiosteoporosis medication: The global longitudinal study of osteoporosis in women (GLOW)

Journal of Bone and Mineral Research

Volumn 29, Issue 1, 2014, Pages 260-267

  Díez Pérez, Adolfo ^a,b   Adachi, Jonathan D ^c   Adami, Silvano ^d   Anderson Jr , Frederick A ^e   Boonen, Steven ^f   Chapurlat, Roland ^g   Compston, Juliet E ^h   Cooper, Cyrus ⁱ   Gehlbach, Stephen H ^e   Greenspan, Susan L ^j   Hooven, Frederick H ^e   Lacroix, Andrea Z ^k   Nieves, Jeri W ^l   Coen Netelenbos, J ^m   Pfeilschifter, Johannes ⁿ   Rossini, Maurizio ^d   Roux, Christian ^o   Saag, Kenneth G ^p   Silverman, Stuart ^q   Siris, Ethel S ^r   Wyman, Allison ^e   Rushton Smith, Sophie K ^e   Watts, Nelson B ^s   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c ST JOSEPH S HOSPITAL   (Canada)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITÉ DE LYON   (France)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k USA   (United States)

^l HELEN HAYES HOSPITAL   (United States)

^m VU UNIVERSITY AMSTERDAM   (Netherlands)

ⁿ ALFRIED KRUPP KRANKENHAUS   (Germany)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r Department of Medicine   (United States)

^s UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

antiresorptive therapy; osteoporosis treatment; risk factors; Treatment failure

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; GLUCOCORTICOID; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE; STRONTIUM RANELATE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; FRACTURE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; OSTEOPOROSIS; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; SHORT FORM 36; STANDING; WEIGHT REDUCTION;

ANTIRESORPTIVE THERAPY; OSTEOPOROSIS TREATMENT; RISK FACTORS; TREATMENT FAILURE;

ACCIDENTAL FALLS; AGED; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 84890917618     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2023     Document Type: Article

References (21)

1. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J., Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148 (3): 197-213.
2. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR., Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282 (7): 637-45.
3. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J., FIT Research Group. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc. 2002; 50 (3): 409-15.
4. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D., Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003; 88 (2): 542-9.
5. Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR., Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res. 2011; 26 (10): 2411-8.
6. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23 (12): 1923-34.
7. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
8. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C., FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-65.
9. Diez-Perez A, Gonzalez-Macias J., Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int. 2008; 19 (11): 1511-6.
10. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C., IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int. 2012; 23 (12): 2769-74.
11. Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris E, Watts NB, Anderson FA Jr., The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int. 2009; 20 (7): 1107-16.
12. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E., FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19 (4): 385-97.
13. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L., Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992; 305 (6846): 160-4.
14. Garvan Institute: fracture risk calculator [Internet].Sydney, Australia: Garvan Institute. 2013. [cited 2013 Jul 22]. Available from.http://www.garvan. org.au/bone-fracture-risk.
15. Levis S, Theodore G., Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012; 18(4 Suppl B):S1-15; discussion S13.
16. Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillon JL, Perez-Cano R, Munoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonzalez-Macias J., Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res. 2012; 27 (4): 817-24.
17. Abrahamsen B, Rubin KH, Eiken PA, Eastell R., Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. Osteoporos Int. 2013; 24 (1): 321-8.
18. Dowd R, Recker RR, Heaney RP., Study subjects and ordinary patients. Osteoporos Int. 2000; 11 (6): 533-6.
19. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R., ICARO Study Group. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res. 2006; 21 (10): 1565-70.
20. Fitzgerald G, Boonen S, Compston JE, Pfeilschifter J, Lacroix AZ, Hosmer DW Jr, Hooven FH, Gehlbach SH., GLOW Investigators. Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2012; 27 (9): 1907-15.
21. Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutte HE, Birkenhager JC, Pols HA., Vertebral deformities and functional impairment in men and women. J Bone Mineral Res. 1997; 12 (1): 152-7.